Loading stock data…
$26.05-0.71 (-2.65%)
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $26.05 with a market capitalization of $986M. Wall Street consensus targets $22.50 (6 analysts), implying a -13.6% move over the next 12 months. The stock is currently 12% below its 52-week high of $29.52, remaining 16.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $183.90M↑ | $171.17M↓ | $183.10M↓ | $191.84M↑ | $174.41M |
| Gross Profit | $93.47M↑ | $70.32M↓ | $85.67M↓ | $98.65M↑ | $86.49M |
| Operating Income | $39.73M↑ | $13.63M↓ | $35.61M↑ | $25.32M↓ | $42.18M |
| Net Income | $30.35M↑ | $6.42M↓ | $24.43M↑ | $17.35M↓ | $31.03M |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...